Physician profile
Jay Chae
NPI 1275237422
$1,827.74
in general payments reported to CMS, 2019-2025
18 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $43.59 · 2024: $118 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $438.19 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $289.25 | 2025 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.20 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $183.99 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $151.31 | 2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $144.07 | 2025 | Auvelity |
| Lundbeck LLC | $94.08 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $80.26 | 2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $46.43 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $35.05 | 2024-2025 | Doc Band |
| Glaxosmithkline, LLC. | $32.97 | 2024 | Bexsero |
| Merck Sharp & Dohme LLC | $26.19 | 2023 | Varivax, Vaxneuvance, Proquad |
| Pfizer INC. | $26.16 | 2024 | |
| Alk-Abello, INC | $23.43 | 2024 | Grastek, Ragwitek, Odactra |
| Verrica Pharmaceuticals INC. | $19.85 | 2024 | Ycanth |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $17.40 | 2023 | Immunocap |
| Tonix Medicines, INC. | $16.50 | 2025 | Tonmya |
| Abbvie INC. | $14.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Chae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.